Literature DB >> 1693704

Interference with human immunodeficiency virus (HIV) replication by CD8+ T cells in peripheral blood leukocytes of asymptomatic HIV carriers in vitro.

M Kannagi1, T Masuda, T Hattori, T Kanoh, K Nasu, N Yamamoto, S Harada.   

Abstract

A long asymptomatic period is one of the characteristics of human immunodeficiency virus (HIV) infection, despite its fatal consequences. Antiviral defense in HIV-infected individuals controls viral replication during this period. In the present study, we demonstrate that peripheral blood leukocytes (PBL) of asymptomatic HIV-1 carriers, following exogenous HIV-1 infection in vitro, do not support viral replication. These cells do not produce detectable amounts of reverse transcriptase or accumulate unintegrated proviral DNA. This is a striking contrast to the behavior of HIV-1-infected PBL of seronegative individuals, which produce large amounts of RT and unintegrated DNA. Such resistance to HIV-1 replication is not seen in PBL of patients with advanced disease. Since the binding of HIV-1 to CD4 molecule is not impaired in PBL of asymptomatic carriers, the interference with HIV replication must occur after the stage of virus binding. PBL lose their resistance when CD8+ lymphocytes are removed. In addition, these PBL are not resistant to an exogenous infection with HIV-2. These observations suggest that certain populations of CD8+ lymphocytes of asymptomatic HIV-1 carriers operate on the target cells in PBL to block viral replication in an HIV-1-specific manner. Such CD8+ lymphocyte-mediated interference with HIV replication could play an important role in the maintenance of the period of disease latency.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693704      PMCID: PMC249592     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Direct detection of HIV RNA expression in seropositive subjects.

Authors:  C Hart; G Schochetman; T Spira; A Lifson; J Moore; J Galphin; J Sninsky; C Y Ou
Journal:  Lancet       Date:  1988-09-10       Impact factor: 79.321

2.  DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells.

Authors:  C Y Ou; S Kwok; S W Mitchell; D H Mack; J J Sninsky; J W Krebs; P Feorino; D Warfield; G Schochetman
Journal:  Science       Date:  1988-01-15       Impact factor: 47.728

3.  Epidemiological parameters of HIV transmission.

Authors:  R M Anderson; R M May
Journal:  Nature       Date:  1988-06-09       Impact factor: 49.962

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack.

Authors:  H K Lyerly; T J Matthews; A J Langlois; D P Bolognesi; K J Weinhold
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

6.  Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.

Authors:  A H Rook; H C Lane; T Folks; S McCoy; H Alter; A S Fauci
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

7.  Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines.

Authors:  G Poli; J M Orenstein; A Kinter; T M Folks; A S Fauci
Journal:  Science       Date:  1989-05-05       Impact factor: 47.728

8.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

9.  Biological characterization of a simian immunodeficiency virus-like retrovirus (HTLV-IV): evidence for CD4-associated molecules required for infection.

Authors:  J A Hoxie; B S Haggarty; S E Bonser; J L Rackowski; H Shan; P J Kanki
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

10.  In vitro growth characteristics of simian T-lymphotropic virus type III.

Authors:  M Kannagi; J M Yetz; N L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

View more
  14 in total

1.  Abrogation of in vitro suppression of human immunodeficiency virus type 1 (HIV-1) replication mediated by CD8+ T lymphocytes of asymptomatic HIV-1 carriers by staphylococcal enterotoxin B and phorbol esters through induction of tumor necrosis factor alpha.

Authors:  M Kubo; T Ohashi; M Fujii; S Oka; A Iwamoto; S Harada; M Kannagi
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 2.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

3.  CD8+ T-cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta, suppress HIV-1 replication in monocyte/macrophages.

Authors:  H Moriuchi; M Moriuchi; C Combadiere; P M Murphy; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

4.  Allo-antigen stimulated CD8+ T-cells suppress NF-κB and Ets-1 DNA binding activity, and inhibit phosphorylated NF-κB p65 nuclear localization in CD4+ T-cells.

Authors:  Ryuichi Nagashima; Fumitaka Kawakami; Shinichiro Takahashi; Fumiya Obata; Makoto Kubo
Journal:  Viral Immunol       Date:  2014-05-20       Impact factor: 2.257

5.  Rapid screening for Mamu-A1-positive rhesus macaques using a SIVmac Gag peptide-specific cytotoxic T-lymphocyte assay.

Authors:  T Vogel; S Norley; B Beer; R Kurth
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

6.  In vitro intersubtype recombinants of human immunodeficiency virus type 1: comparison to recent and circulating in vivo recombinant forms.

Authors:  Miguel E Quiñones-Mateu; Yong Gao; Sarah C Ball; Andre J Marozsan; Awet Abraha; Eric J Arts
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Evidence for CD8+ antiviral activity in cats infected with feline immunodeficiency virus.

Authors:  C R Jeng; R V English; T Childers; M B Tompkins; W A Tompkins
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism.

Authors:  C M Walker; A L Erickson; F C Hsueh; J A Levy
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

Review 9.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

10.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.